Clinical Report: Safety Evaluation of Ponatinib: Insights from a Decade of Real-World Data

Overview

A decade of real-world safety data indicates that risk management measures (RMMs) implemented for ponatinib have led to a decrease in important identified risks (IIRs) associated with its use in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia. This report evaluates the long-term safety profile of ponatinib and the effectiveness of RMMs.

Background

Ponatinib is a third-generation BCR::ABL1 tyrosine kinase inhibitor that has been used in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Following its approval, safety concerns regarding vascular occlusive events (VOEs) prompted the implementation of risk management measures to enhance patient safety.

Data Highlights

Real-world data over a decade shows a decrease in VOEs and other important identified risks (IIRs) following the implementation of risk management measures for ponatinib.

Key Findings

• Risk management measures (RMMs) were implemented after safety signals regarding vascular occlusive events (VOEs) were identified.
• Post-approval RMMs included revised prescribing information and healthcare professional communications to manage risks associated with ponatinib.
• A retrospective analysis in 2022 provided a characterization of arterial occlusive events (AOEs) related to ponatinib.
• Long-term safety data indicates a reduction in important identified risks (IIRs) associated with ponatinib use.
• The OPTIC trial evaluated a response-based dosing strategy in patients with chronic phase CML.

Clinical Implications

Ongoing safety monitoring is essential in managing adverse events associated with ponatinib.

Conclusion

The evaluation of a decade's worth of real-world data indicates that risk management measures have been implemented to address safety risks associated with ponatinib.

Related Resources & Content

1. The ASCO Post, 2013 -- Pivotal Trial Shows Robust Activity of Ponatinib in Some Heavily Pretreated Leukemias
2. Blood Cancer Journal, 2023 -- Clinical Insights on Ponatinib Treatment for Chronic Phase Chronic Myeloid Leukemia: Effects of Response Depth on Survival and Previous Nilotinib Use on Vascular Events
3. The ASCO Post, 2012 -- PACE Trial Update: Ponatinib Produces High Response Rates in CML Related Articles
4. European Medicines Agency (EMA), 2023 -- PRAC recommends further measures to minimise risk of blood vessel blockage with Iclusig
5. Journal of Clinical Oncology, 2024 -- Ponatinib (PON) in patients with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC.
6. The ASCO Post — Expert Point of View: Anjali S. Advani, MD Related Articles
7. Chronic Myeloid Leukemia Treatment (PDQ®) - NCI
8. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia - PMC
9. PRAC recommends further measures to minimise risk of blood vessel blockage with Iclusig | European Medicines Agency (EMA)
10. Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC. | Journal of Clinical Oncology
11. ICLUSIG (ponatinib) tablets, for oral use — Highlights of Prescribing Information
12. FDA grants accelerated approval to ponatinib with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia | FDA
13. ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia - PubMed
14. Paper: Blinatumomab and Ponatinib for Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results and Predictors of Relapse